Introduction
============

Head and neck squamous cell carcinoma (HNSCC) is a rare cancer \[[@b1-crt-2018-411]\]. Recurrence and metastasis occur in about one third of all HNSCC patients. When recurrence or metastasis occurs, the outcomes are dismal \[[@b2-crt-2018-411]\]. Therefore, it is desirable to have alternative treatment options for such cases.

Oropharyngeal cancer, in contrast to other non-oropharyngeal head and neck cancers, is known to be related to human papilloma virus (HPV) infection, and patients with HPV-positive oropharyngeal cancer have a better prognosis than those with HPV-negative cancer \[[@b3-crt-2018-411]\]. According to the recent World Health Organization (WHO) classification \[[@b4-crt-2018-411],[@b5-crt-2018-411]\], oropharyngeal squamous cell carcinoma (SCC) is classified as HPV-positive and HPV-negative oropharyngeal SCC. Regarding 'HPV-positive' and 'HPV-negative,' the new WHO classification \[[@b4-crt-2018-411],[@b5-crt-2018-411]\] specifically note p16 immunohistochemistry alone (with appropriate criteria for a positive versus negative test) as a suitable surrogate marker and recommend the terminology HPV-positive even if only p16 is performed. Using moderate to intense nuclear and cytoplasmic p16 immunohistochemistry in 70% or more of the tumor cells as surrogate marker for HPV status has been widely validated, especially in oropharyngeal SCC \[[@b6-crt-2018-411],[@b7-crt-2018-411]\]. HPV status appears to affect tumor characteristics in patients with oropharyngeal cancer, but the underlying mechanism has not yet been clarified.

Trophomyosin-related kinases (Trk), namely TrkA, TrkB, and TrkC, belong to a family of neurotrophin receptor tyrosine kinases and are encoded by the *NTRK1*, *NTRK2*, and *NTRK3* genes, respectively. TrkA, TrkB, and TrkC bind to nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3, respectively \[[@b8-crt-2018-411]\]. In HNSCC, TrkB is known to be overexpressed and related to oncogenesis, tumor progression, and conventional chemotherapy resistance \[[@b9-crt-2018-411],[@b10-crt-2018-411]\].

While attempts to describe Trk expression patterns have drawn increasing interest, Trk expression status has rarely been studied in clinical samples of HNSCC. In this study, we sought to evaluate the expression status of Trk in oropharyngeal cancer and non-oropharyngeal cancer and to determine its clinicopathological significance. In addition, possible associations between HPV status, p16 expression and Trk protein expression were investigated.

Materials and Methods
=====================

1. Patients, samples, and clinical data
---------------------------------------

Formalin-fixed, paraffin-embedded (FFPE) specimens were obtained from consecutive HNSCC patients who underwent surgical resection with curative aim at Severance Hospital, Seoul, Korea, between 2005 and 2012. Appropriate cases were selected from among the archived cases. Inclusion criteria were as follows: available tumor tissue, relevant clinical data regarding smoking status and survival data, absence of preoperative treatment, and no clinicopathologic evidence of distant metastasis at the time of surgery. We excluded HNSCC tissue samples that had been subjected to decalcification for accurate immunohistochemistry. Ultimately, 121 oropharyngeal cases and 275 non-oropharyngeal cases, total 396 cases were selected, among which complete R0 resection, defined histologically as tumor-free resection margins, achieved in 305 ([S1 Table](#SD1-crt-2018-411){ref-type="supplementary-material"}). Several pathologic factors, including tumor size, lymphovascular invasion, perineural invasion, pathologic TNM staging, according to the 7th American Joint Committee on Cancer (AJCC) criteria and tumor classification by the WHO system \[[@b11-crt-2018-411],[@b12-crt-2018-411]\], were obtained from the slide review by two individual pathologists (Y.A. Cho and S.O. Yoon). Clinical data and survival outcomes were collected and reviewed from patients' medical records. The median follow-up period was 37.1 months (range, 0.8 to 99.6 months). Other clinicopathologic characteristics are described in [S1 Table](#SD1-crt-2018-411){ref-type="supplementary-material"}.

2. Tissue microarray preparation
--------------------------------

Sections of FFPE tissues were prepared and stained with hematoxylin and eosin. Representative tumor areas were confirmed microscopically, selected two or three different representative areas per case, and used for tissue microarray (TMA) construction as previously described \[[@b13-crt-2018-411]\].

3. Immunohistochemistry and interpretation
------------------------------------------

Immunohistochemistry was performed on 4-μm TMA tissue sections with a Ventana Bench Mark XT Autostainer (Ventana Medical Systems, Tucson, AZ) as described in previous reports \[[@b14-crt-2018-411],[@b15-crt-2018-411]\]. The following primary antibodies were tested: anti-TrkA antibody (1:100 dilution, EP1058Y, rabbit monoclonal antibody, Abcam, Cambridge, MA), anti-TrkB antibody (1:300 dilution, ab18987, rabbit polyclonal antibody, Abcam), anti-panTrk (1:100 dilution, Trk A+B+C, EPR17341, rabbit monoclonal antibody, Abcam), and p16 (E03347, mouse monoclonal antibody, RTU, Ventana Medical Systems).

Expression of Trk subtypes was analyzed according to the semi-quantitative H-score method; this method yields a total score range of 0-300 as previously described \[[@b16-crt-2018-411]\]. The intensity of expression was scored by cytoplasmic staining only ([Fig. 1A](#f1-crt-2018-411){ref-type="fig"}-[D](#f1-crt-2018-411){ref-type="fig"}). Conventionally accepted criteria were used for p16 immunohistochemistry as previously described. Positive and negative pattern is described in [Fig. 1E](#f1-crt-2018-411){ref-type="fig"} and [F](#f1-crt-2018-411){ref-type="fig"} respectively \[[@b17-crt-2018-411]-[@b22-crt-2018-411]\].

4. Cell lines and culture
-------------------------

HNSCC cell lines FaDu, a cell line derived from HPV-negative pharynx SCC, and CAL27, a cell line derived from HPV-negative tongue SCC were prepared. FaDu cell line was maintained in RPMI-1640 medium (22400-089, Gibco, Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS; 5000-044, Gibco, Life Technologies). CAL27 and UMSCC 47 cell lines were maintained in Dulbecco\'s modified Eagle\'s medium (SH30243.01, HyClone, Thermo Scientific, Logan, UT) supplemented with 10% FBS (6000-044, Gibco, Life Technologies).

5. Transfection with HPV gene
-----------------------------

Plasmid p1321 HPV-16 E6/E7 or empty plasmid vector (Addgene, Cambridge, MA) was transfected into each cell-line of FaDu and CAL27 by using TransIT-X2 Dynamic Delivery System (Mirus, Madison, WI).

6. RNA isolation and real-time polymerase chain reaction
--------------------------------------------------------

RNA was isolated after 24 hours and 48 hours of transfection using RNeasy plus mini kit (Qiagen, Valencia, CA). cDNA was made using qPCRBIO cDNA synthesis kit (PCR Biosystems, London, UK). Primers of GAPDH, E6, E7, TrkA, TrkB, and TrkC were manufactured (Integrated DNA Technologies, Skokie, IL), and primer sequences were summarized in [S2 Table](#SD2-crt-2018-411){ref-type="supplementary-material"}. Quantitative polymerase chain reaction (PCR) was performed using 2× qPCRBIO SyGreen Mix Lo-Rox (PCR Biosystems) as PCR reagent and ABI 7500 Real-Time PCR System (Applied Biosystems, Thermo Fisher Scientific) with the following cycling parameters: 95°C for 2 minutes, 40 cycles of 95°C for 5 seconds and 60°C for 30 seconds, 95°C for 15 seconds, and 60°C for 10 minutes. Relative mRNA expression levels were determined by the comparative method (2^-ddCt^).

7. Statistical analysis
-----------------------

Statistical analyses were conducted using IBM SPSS ver. 22 software for Windows (IBM Corp., Armonk, NY). The Mann-Whitney U test, Kruskal-Wallis test and chi-square test, were used to analyze the significance of differences between the evaluated variables. Overall survival (OS) was measured from the date of initial diagnosis to that of death or the last follow-up visit. Recurrence-free survival (RFS) was measured from the date of initial diagnosis to that of disease progression, defined as cancer recurrence, continuance of stable disease/partial remission/progressive disease without complete remission, or cancer-related death during the study period. The Kaplan-Meier method was used to analyze survival rates, and differences were compared using the log-rank test. Multivariate regression analysis was performed using a Cox proportional hazards model. Two-sided p-values \< 0.05 were considered statistically significant.

8. Ethical statement
--------------------

This study was approved by the Institutional Review Board of Severance Hospital with a waiver of informed consent (No. 4-2015-0954).

Results
=======

1. Expression status of Trk protein according to anatomical site and p16 expression
-----------------------------------------------------------------------------------

In overall HNSCC cases, TrkA expression was on average 91.8 (range, 0 to 230), TrkB 36.8 (range, 0 to 278), and panTrk 79.2 (range, 0 to 263) among all HNSCC cases ([S3 Fig.](#SD3-crt-2018-411){ref-type="supplementary-material"}). Trk expression varied among anatomical sites. Expression of TrkA and panTrk was significantly higher in oropharyngeal SCCs than non-oropharyngeal SCCs. Also both expressions were significantly higher in p16 positive HNSCCs than negative cases. However, TrkB expression showed no correlation with anatomical sites and p16 status ([Fig. 2A](#f2-crt-2018-411){ref-type="fig"} and [B](#f2-crt-2018-411){ref-type="fig"}, [S4](#SD4-crt-2018-411){ref-type="supplementary-material"} and [S5 Figs.](#SD5-crt-2018-411){ref-type="supplementary-material"}).

2. Alteration of Trk protein expression by HPV gene transfection
----------------------------------------------------------------

After transfection of HPV-16 E6/E7 gene inserted plasmid, significant increase of E6 and E7 gene expression was confirmed at the time of 24 and 48 hours after transfection ([S6 Fig.](#SD6-crt-2018-411){ref-type="supplementary-material"}). The levels of TrkA, TrkB and TrkC mRNA level were measured 48 hours after transfection; and both FaDu and CAL27 transfected with HPV-16 E6/E7 genes revealed increased \|expression of TrkA and TrkC when compared to control ([Fig. 3A](#f3-crt-2018-411){ref-type="fig"}, [B](#f3-crt-2018-411){ref-type="fig"}, [E](#f3-crt-2018-411){ref-type="fig"} and [F](#f3-crt-2018-411){ref-type="fig"}). TrkB gene expression showed a tendency of decreased expression after HPV-16 E6/E7 gene transfection ([Fig. 3C](#f3-crt-2018-411){ref-type="fig"} and [D](#f3-crt-2018-411){ref-type="fig"}).

3. Clinicopathological characteristics in conjunction with Trk expression
-------------------------------------------------------------------------

Among all HNSCC cases, high TrkA and panTrk expression was significantly associated with the presence of lymphovascular invasion and p16 expression ([Table 1](#t1-crt-2018-411){ref-type="table"}). In addition, high panTrk expression was significantly associated with the presence of lymph node metastasis (p \< 0.001). However, other clinicopathologic variables were not related to the expression of TrkA and panTrk proteins ([Table 1](#t1-crt-2018-411){ref-type="table"}). In oropharyngeal HNSCCs, only p16 expression was significantly associated with TrkA and panTrk protein expression (p \< 0.001 and p=0.038, respectively) ([Table 2](#t2-crt-2018-411){ref-type="table"}). However, panTrk expression was significantly correlated with the presence of lymphovascular invasion (p \< 0.001), presence of perineural invasion (p=0.007), advanced pathologic T category (p=0.045), and presence of lymph node metastasis (p=0.002) in non-oropharyngeal HNSCC ([Table 3](#t3-crt-2018-411){ref-type="table"}). Both TrkA and panTrk expression showed no significant correlation with perinodal soft tissue extension status. TrkB expression status showed no statistically significant correlation with any of the clinico-pathologic factors ([S7 Table](#SD7-crt-2018-411){ref-type="supplementary-material"}).

4. Prognostic impact of Trk protein expression on HNSCC patients
----------------------------------------------------------------

Among R0 resected HNSCCs (n=305), five cases were not available for Kaplan-Meier analysis due to the absence of follow-up data. Among 300 cases of R0 resected HNSCCs, high TrkA expression showed a tendency to be related to superior OS ([Fig. 4A](#f4-crt-2018-411){ref-type="fig"}), although it was not associated with RFS ([Fig. 4B](#f4-crt-2018-411){ref-type="fig"}). Especially in R0-resected oropharyngeal SCCs (n=82), high TrkA expression was significantly related to superior OS ([Fig. 4C](#f4-crt-2018-411){ref-type="fig"}) and RFS ([Fig. 4D](#f4-crt-2018-411){ref-type="fig"}). In non-oropharyngeal SCCs, especially in those of oral cavity (n=181), high panTrk expression tended to be related to poor OS and inferior RFS than those with low panTrk expression ([Fig. 4E](#f4-crt-2018-411){ref-type="fig"} and [F](#f4-crt-2018-411){ref-type="fig"}). TrkB expression was not related to OS or RFS in oropharyngeal or non-oropharyngeal SCCs ([S8 Fig.](#SD8-crt-2018-411){ref-type="supplementary-material"}). Other nonoropharyngeal SCCs showed no significant correlation with the expression of TrkA and panTRK protein in Kaplan-Meier analysis ([S9](#SD9-crt-2018-411){ref-type="supplementary-material"} and [S10 Figs.](#SD10-crt-2018-411){ref-type="supplementary-material"}).

In multivariate Cox analysis in R0 resected oropharyngeal HNSCC, only p16 expression status and pathologic T category acts as independent prognostic factors for OS and RFS ([Table 4](#t4-crt-2018-411){ref-type="table"}). However, in R0 resected oral cavity HNSCCs, age, presence of lymphovascular invasion and advanced pathologic T category were independent factors for OS and RFS ([S11 Table](#SD11-crt-2018-411){ref-type="supplementary-material"}). Higher panTrk expression tends to relate with inferior RFS in multivariate analysis (p=0.060) ([S11 Table](#SD11-crt-2018-411){ref-type="supplementary-material"}). In Kaplan-Meier analysis of 91 R1-resected head and neck squamous cell carcinomas in association with Trk expression, no significant difference was observed in OS and RFS according to TrkA, panTRkA, or TrkB expression ([S12 Fig.](#SD12-crt-2018-411){ref-type="supplementary-material"}).

Discussion
==========

In this study, we evaluated and compared the expression status of subtypes of Trk in oropharyngeal cancer and non-oropharyngeal cancer and investigated the relationship between the expression levels of these subtypes and p16 expression status, clinicopathological variables, and patient prognosis.

In our study, cytoplasmic staining of tumors varied in intensity. Recent studies have described the reliability of pan-Trk and TrkA immunohistochemical staining in the prediction of *NTRK* gene alteration \[[@b23-crt-2018-411]-[@b25-crt-2018-411]\]: one study reported 15 cases of positive pan-Trk positive staining in 16 cases of known NTRK fusions. Interestingly, cytoplasmic staining accompanied by other expression patterns has been found to be associated with specific NTRK fusion patterns: *EML4-NTRK3* fusion with nuclear staining, *LMNA-NTK1* fusion with nuclear membrane staining, and *TPM3/4-NTRK1/3* and *TRAF2-NTRK2* fusion with membranous staining \[[@b24-crt-2018-411]\]. Also, research suggest that strong cytoplasmic TrkA expression might be related with *NTRK1* gene fusion in colorectal cancers \[[@b23-crt-2018-411]\] and might be indicative of gene copy number gain in solid tumors, such as lung adenocarcinoma, and colon and bile duct cancer \[[@b25-crt-2018-411]\].

We observed that TrkA and panTrk were expressed more highly in oropharyngeal than non-oropharyngeal SCCs. Oropharyngeal cancer shows a significant association with HPV infection, in contrast to non-oropharyngeal SCC. Carcinomas driven by HPV infection induce p16 protein overexpression through loss of control over cell cycle regulation; therefore, p16 immunohistochemistry is a reliable surrogate marker for HPV infection \[[@b18-crt-2018-411],[@b19-crt-2018-411],[@b21-crt-2018-411],[@b22-crt-2018-411],[@b26-crt-2018-411],[@b27-crt-2018-411]\]. These previous findings and those of the present study suggest that high expression of TrkA and panTrk might be related to HPV-driven molecular changes during the carcinogenesis of oropharyngeal SCCs. In the present study, HPV gene transfection on the originally HPV-negative HNSCC cell-lines altered TrkA and TrkB gene expression. Especially, the increment of TrkA and TrkC gene expression after HPV gene transfection reflects our observation about the close correlation between high TrkA and panTrk (A+B+C) expression and p16 positive HNSCC cases. From the findings, HPV infection may play a role in regulation of TrkA and TrkC expression. Further in-depth studies are needed for the detailed mechanisms related to the interaction between HPV infection and each Trk subtype regulation.

Besides HPV infection, genetic alteration may be related to alter Trk expression. According to recent The Cancer Genome Atlas data for HNSCCs (530 samples/528 patients; [www.cbioportal.org/study?id=hnsc_tcga\#summary](http://www.cbioportal.org/study?id=hnsc_tcga#summary)); however, mutations of the *NTRK*1, 2, and 3 genes have a very low frequency (0.6%, 0.6%, and 2.1%, respectively), and copy number alterations (amp-lifications or deletions) are also low frequency (1.2%, 0.8%, and 0.6%, respectively). These findings suggest that genetic mutations or copy number alterations are not the major factors underlying TrkA and panTrk overexpression in HNSCCs. A recent study of colorectal adenocarcinomas reported that high TrkA protein expression was related to *NTRK1* gene rearrangement \[[@b28-crt-2018-411]\]. Although colorectal adenocarcinomas are very different from HNSCCs in terms of anatomical origin, histology, and biology of carcinogenesis, investigation of *NTRK* gene rearrangements should be performed to gain insights into the mechanism underlying TrkA and panTrk overexpression in HNSCCs.

In the present study, high TrkA expression was related to favorable prognosis. Given that HPV-positive oropharyngeal SCCs have a more favorable prognosis than HPV-negative carcinomas \[[@b29-crt-2018-411]\], and that high TrkA expression was associated with p16 positivity in the present study, close association between high TrkA expression and the favorable outcome of oropharyngeal SCCs may be related to HPV infection. Further in-depth study, however, may be necessary about the relations among HPV infection, Trk regulation, tumor cell growth.

In contrast, high panTrk expression was related to poor outcomes in patients with oral cavity SCCs, but couldn't prove as independent prognostic factor for OS and RFS. Regarding previous studies about pancreatic cancer and adenoid cystic carcinoma \[[@b30-crt-2018-411],[@b31-crt-2018-411]\], overexpression of Trk protein is associated with tumor metastasis or perineural invasion which is concordant with our result. Given that panTrk includes TrkA, B, and C, among TrkA, B, and C or the combination of these Trk subtypes affects lymphovascular invasion and perineural invasion and contribute to the poor outcome in patients with oral cavity SCCs. However, we were not able to assess TrkC protein expression by immunohistochemistry, because of the lack of commercially available and reliable antibodies. Although further studies are required to identify the prognostic relevance of TrkC, oral cavity SCCs showing high panTrk expression may be candidates for treatment with panTrk inhibitors.

In previous *in vitro* study, TrkB expression may be related with tumor proliferation and chemotherapy resistance \[[@b32-crt-2018-411]-[@b34-crt-2018-411]\]. However, we could not prove the relationship between TrkB expression and OS or RFS. This might be limitation of immunohistochemical staining of TrkB protein. Since our study cohort is composed of surgically resected specimen without prior therapy, there may be need for TrkB expression status in samples of recurrent HNSCC or chemotherapy-resistant cases.

Trk protein expression seems to differ according to anatomical site and p16 expression or HPV status with clinical relevance. As a result, Trk expression status should be considered in the context of anatomical site and Trk subtype when considering treatment using Trk inhibitors.
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![Expression pattern of Trk protein and p16 using immunohistochemistry (×200). Representative expression as assessed by Trk immunohistochemistry: Trk showed diffuse cytoplasmic staining in tumor cells. The four cases shown had different intensities of Trk expression in all tumor cells. (A) Negative, H-score 0. (B) Intensity 1, H-score 100. (C) Intensity 2, H-score 200. (D) Intensity 3, H-score 300. Strong and diffuse nuclear and cytoplasmic staining of p16 immunohistochemical staining (E) and negative staining was observed (F).](crt-2018-411f1){#f1-crt-2018-411}

![Expression of Trk protein in head and neck squamous cell carcinomas according to anatomical location and p16 status. (A) H-scores of TrkA and panTrk were significantly higher at oropharyngeal sites than non-oropharyngeal areas (p \< 0.001). However, there was no significant difference in H-scores of TrkB according to anatomical site. (B) H-scores of TrkA and panTrk were higher in p16 positive cases than p16 negative cases. No significant difference was observed in the H-score of TrkB between p16 positive cases and p16 negative cases.](crt-2018-411f2){#f2-crt-2018-411}

![Alteration of TrkA and TrkB expression and proliferation ability by HPV-16 oncogene. (A) Increased level of TrkA mRNA 48 hours after transfection in FaDu cell line. (B) Increased level of TrkA mRNA 48 hours after transfection in CAL-27 cell-line. (C) Slight decreased level of TrkB mRNA in FaDu cell line. (D) Decreased level of TrkB in CAL27 cell line. Increased level of TrkC mRNA 48 hours after transfection in FaDu cell line (E) and CAL27 cell line (F). CTR, transfection with empty vector; HPV, transfection with HPV-16 oncogene.](crt-2018-411f3){#f3-crt-2018-411}

![Kaplan-Meier analysis of R0-resected head and neck squamous cell carcinomas (SCCs) in aspect of anatomical sites. (A) In the analysis of 300 R0 resected cases, TrkA high expression group tended to have a longer overall survival (OS) than the Trk low expression group (p=0.060). (B) No significant difference was observed in recurrence-free survival (RFS) according to TrkA expression status (p=0.348). (C) In the analysis of 82 R0 resected oropharyngeal SCCs, TrkA high group had a significantly longer OS than the TrkA low expression group (p=0.044). (D) In addition, the TrkA high group showed longer RFS than the TrkA low expression group (p=0.032). (E) In 180 R0 resected oral cavity SCCs, high panTrk expression tended to be related to poor OS (p=0.065). (F) Furthermore, the high panTrk group showed a significantly inferior RFS than the low panTrk group (p=0.001).](crt-2018-411f4){#f4-crt-2018-411}

###### 

Clinicopathological characteristics of 391 HNSCCs according to TrkA and panTrk expression status

  Variable                                                                             No. (n=391)^[a)](#tfn1-crt-2018-411){ref-type="table-fn"}^   TrkA expression   p-value      panTrk expression   p-value                   
  ------------------------------------------------------------------------------------ ------------------------------------------------------------ ----------------- ------------ ------------------- ------------ ------------ ----------
  **Age (yr)**                                                                                                                                                                                                                   
   \< 58                                                                               190                                                          76 (47.5)         114 (49.4)   0.758               73 (43.2)    117 (52.7)   0.067
   ≥ 58                                                                                201                                                          84 (52.5)         117 (50.6)                       96 (56.8)    105 (47.3)   
  **Sex**                                                                                                                                                                                                                        
   Female                                                                              97                                                           40 (25.0)         57 (24.7)    \> 0.999            34 (20.1)    63 (28.4)    0.076
   Male                                                                                294                                                          120 (75.0)        175 (75.3)                       135 (79.9)   159 (71.6)   
  **Location**                                                                                                                                                                                                                   
   Hypopharynx                                                                         28                                                           8 (5.0)           20 (8.7)     0.011               13 (7.7)     15 (6.8)     \< 0.001
   Larynx                                                                              42                                                           12 (7.5)          30 (13.0)                        16 (9.5)     26 (11.7)    
   Oral cavity                                                                         200                                                          77 (48.1)         123 (53.2)                       57 (33.7)    143 (64.4)   
   Oropharynx                                                                          121                                                          63 (39.4)         58 (25.1)                        83 (49.1)    38 (17.1)    
  **Smoking**                                                                                                                                                                                                                    
   Non-smoker                                                                          151                                                          70 (43.8)         81 (35.1)    0.214               55 (32.5)    96 (43.2)    0.085
   Ex-smoker                                                                           80                                                           29 (18.1)         51 (22.1)                        40 (23.7)    40 (18.0)    
   Smoker                                                                              160                                                          61 (38.1)         99 (42.9)                        74 (43.8)    86 (38.7)    
  **p16 IHC status**                                                                                                                                                                                                             
   Negative                                                                            269                                                          88 (55.0)         181 (78.4)   \< 0.001            86 (50.9)    183 (82.4)   \< 0.001
   Positive                                                                            122                                                          72 (45.0)         50 (21.6)                        83 (49.1)    39 (17.6)    
  **Lymphovascular invasion**                                                                                                                                                                                                    
   Absent                                                                              315                                                          118 (73.8)        197 (85.3)   0.004               119 (70.4)   196 (88.3)   \< 0.001
   Present                                                                             76                                                           42 (26.3)         34 (14.7)                        50 (29.6)    26 (11.7)    
  **Perineural invasion**                                                                                                                                                                                                        
   Absent                                                                              337                                                          132 (82.5)        205 (88.7)   0.054               139 (82.2)   198 (89.2)   0.055
   Present                                                                             54                                                           28 (17.5)         26 (11.3)                        30 (17.8)    24 (10.8)    
  **Pathologic T category**                                                                                                                                                                                                      
   pT1-2                                                                               321                                                          128 (80.0)        193 (83.5)   0.421               133 (78.7)   188 (84.7)   0.143
   pT3-4                                                                               70                                                           32 (20.0)         38 (16.5)                        36 (21.3)    34 (15.3)    
  **Lymph node metastasis**                                                                                                                                                                                                      
   Absent                                                                              172                                                          62 (38.8)         110 (47.6)   0.097               53 (31.4)    119 (53.6)   \< 0.001
   Present                                                                             219                                                          98 (61.3)         121 (52.4)                       116 (68.6)   103 (46.4)   
  **Perinodal soft tissue extension^[b)](#tfn2-crt-2018-411){ref-type="table-fn"}^**                                                                                                                                             
   Absent                                                                              52                                                           25 (34.7)         27 (35.1)    \> 0.999            24 (29.6)    28 (41.2)    0.169
   Present                                                                             97                                                           47 (65.3)         50 (64.9)                        57 (70.4)    40 (58.8)    

Values are presented as number (%). HNSCC, head and neck squamous cell carcinoma; IHC, immunohistochemistry.

TrkA and PanTrk immunohistochemistry was performed in all 396 cases but five cases could not be interpreted because of a damaged core,

The perinodal soft tissue extension status was evaluated in 149 HNSCC cases.

###### 

Clinicopathological characteristics of 121 oropharyngeal HNSCCs according to TrkA and panTrk expression status

  Variable                                                                             No. (n=121)   TrkA expression   p-value     panTrk expression   p-value                 
  ------------------------------------------------------------------------------------ ------------- ----------------- ----------- ------------------- ----------- ----------- ----------
  **Age (yr)**                                                                                                                                                                 
   \< 58                                                                               57            27 (42.9)         30 (51.7)   0.365               38 (45.8)   19 (50.0)   0.698
   ≥ 58                                                                                64            36 (57.1)         28 (48.3)                       45 (54.2)   19 (50.0)   
  **Sex**                                                                                                                                                                      
   Female                                                                              20            8 (12.7)          12 (20.7)   0.328               14 (16.9)   6 (15.8)    \> 0.999
   Male                                                                                101           55 (87.3)         46 (79.3)                       69 (83.1)   32 (84.2)   
  **Smoking**                                                                                                                                                                  
   Non-smoker                                                                          38            22 (34.9)         16 (27.6)   0.676               26 (31.3)   12 (31.6)   0.345
   Ex-smoker                                                                           25            12 (19.0)         13 (22.4)                       20 (24.1)   5 (13.2)    
   Smoker                                                                              58            29 (46.0)         29 (50.0)                       37 (44.6)   21 (55.2)   
  **p16 IHC status**                                                                                                                                                           
   Negative                                                                            29            6 (9.5)           23 (39.7)   \< 0.001            15 (18.1)   14 (36.8)   0.038
   Positive                                                                            92            57 (90.5)         35 (60.3)                       68 (81.9)   24 (63.2)   
  **Lymphovascular invasion**                                                                                                                                                  
   Absent                                                                              81            39 (61.9)         42 (72.4)   0.250               54 (65.1)   27 (71.1)   0.541
   Present                                                                             40            24 (38.1)         16 (27.6)                       29 (34.9)   11 (28.9)   
  **Perineural invasion**                                                                                                                                                      
   Absent                                                                              111           56 (88.9)         55 (94.8)   0.327               75 (90.4)   36 (94.7)   0.503
   Present                                                                             10            7 (11.1)          3 (5.2)                         8 (9.6)     2 (5.3)     
  **Pathologic T category**                                                                                                                                                    
   pT1-2                                                                               101           50 (79.4)         51 (87.9)   0.230               69 (83.1)   32 (84.2)   \> 0.999
   pT3-4                                                                               20            13 (20.6)         7 (12.1)                        14 (16.9)   6 (15.8)    
  **Lymph node metastasis**                                                                                                                                                    
   Absent                                                                              23            12 (19.0)         11 (19.0)   \> 0.999            18 (21.7)   5 (13.2)    0.325
   Present                                                                             98            51 (81.0)         47 (81.0)                       65 (78.3)   33 (86.8)   
  **Perinodal soft tissue extension^[a)](#tfn3-crt-2018-411){ref-type="table-fn"}^**                                                                                           
   Absent                                                                              22            13 (32.5)         9 (31.0)    \> 0.999            13 (27.7)   9 (40.9)    0.284
   Present                                                                             47            27 (67.5)         20 (69.0)                       34 (72.3)   13 (59.1)   

Values are presented as number (%). HNSCC, head and neck squamous cell carcinoma; IHC, immunohistochemistry.

The perinodal soft tissue extension status was evaluated in 69 oropharyngeal HNSCC cases.

###### 

Clinicopathological characteristics of 270 non-oropharyngeal HNSCCs according to Trk expression status

  Variable                                                                             No. (n=270)^[a)](#tfn4-crt-2018-411){ref-type="table-fn"}^   TrkA expression   p-value      panTrk expression   p-value                  
  ------------------------------------------------------------------------------------ ------------------------------------------------------------ ----------------- ------------ ------------------- ----------- ------------ ----------
  **Age (yr)**                                                                                                                                                                                                                  
   \< 58                                                                               133                                                          49 (50.5)         84 (48.6)    0.800               35 (40.7)   98 (53.3)    0.067
   ≥ 58                                                                                137                                                          48 (49.5)         89 (51.4)                        51 (59.3)   86 (46.7)    
  **Sex**                                                                                                                                                                                                                       
   Female                                                                              77                                                           32 (33.0)         45 (26.0)    0.261               20 (23.3)   57 (31.0)    0.247
   Male                                                                                193                                                          65 (67.0)         128 (74.0)                       66 (76.7)   127 (69.0)   
  **Smoking**                                                                                                                                                                                                                   
   Non-smoker                                                                          113                                                          48 (49.5)         65 (37.6)    0.163               29 (33.7)   84 (45.7)    0.180
   Ex-smoker                                                                           55                                                           17 (17.5)         38 (22.0)                        20 (23.3)   35 (19.0)    
   Smoker                                                                              102                                                          32 (33.0)         70 (40.5)                        37 (43.0)   65 (35.3)    
  **p16 IHC status**                                                                                                                                                                                                            
   Negative                                                                            240                                                          82 (84.5)         158 (91.3)   0.107               71 (82.6)   169 (91.8)   0.036
   Positive                                                                            30                                                           15 (15.5)         15 (8.7)                         15 (17.4)   15 (8.2)     
  **Lymphovascular invasion**                                                                                                                                                                                                   
   Absent                                                                              234                                                          79 (81.4)         155 (89.6)   0.064               65 (75.6)   169 (91.8)   \< 0.001
   Present                                                                             36                                                           18 (18.6)         18 (10.4)                        21 (24.4)   15 (8.2)     
  **Perineural invasion**                                                                                                                                                                                                       
   Absent                                                                              226                                                          76 (78.4)         150 (86.7)   0.087               64 (74.4)   162 (88.0)   0.007
   Present                                                                             44                                                           21 (21.6)         23 (13.3)                        22 (25.6)   22 (12.0)    
  **Pathologic T category**                                                                                                                                                                                                     
   pT1-2                                                                               220                                                          78 (80.4)         142 (82.1)   0.746               64 (74.4)   156 (84.8)   0.045
   pT3-4                                                                               50                                                           19 (19.6)         31 (17.9)                        22 (25.6)   28 (15.2)    
  **Lymph node metastasis**                                                                                                                                                                                                     
   Absent                                                                              149                                                          50 (51.5)         99 (57.2)    \> 0.999            35 (40.7)   114 (62.0)   0.002
   Present                                                                             121                                                          47 (48.5)         74 (42.8)                        51 (59.3)   70 (38.0)    
  **Perinodal soft tissue extension^[b)](#tfn5-crt-2018-411){ref-type="table-fn"}^**                                                                                                                                            
   Absent                                                                              30                                                           12 (37.5)         18 (37.5)    \> 0.999            11 (32.4)   19 (41.3)    0.487
   Present                                                                             50                                                           20 (62.5)         30 (62.5)                        23 (67.6)   27 (58.7)    

Values are presented as number (%). HNSCC, head and neck squamous cell carcinoma; IHC, immunohistochemistry.

Trk immunohistochemistry was performed in all 275 cases but five cases could not be interpreted because of a damaged core,

The perinodal soft tissue extension status was evaluated in 80 non-oropharyngeal HNSCC cases.

###### 

Univariate and multivariate analysis of RFS and OS in R0 resected oropharyngeal HNSCC (n=82)

  Variable                                                      OS                     RFS                                                                                         
  ------------------------------------------------------------- ---------------------- ------- ----------------------- ------- --------------------- ------- --------------------- -------
  **Age (yr)^[a)](#tfn6-crt-2018-411){ref-type="table-fn"}^**                                                                                                                      
   \< 58                                                        1                              \-                              1                             \-                    
   ≥ 58                                                         0.414 (0.076-2.264)    0.309   \-                      \-      0.978 (0.297-3.217)   0.970   \-                    \-
  **Sex**                                                                                                                                                                          
   Female                                                       1                              \-                              1                             \-                    
   Male                                                         3.291 (0.097-112.2)    0.508   \-                      \-      3.395 (0.285-48.89)   0.333   \-                    \-
  **Smoking**                                                                                                                                                                      
   Non-smoker                                                   1                              \-                              1                             \-                    
   Ex-smoker                                                    2.220 (0.070-70.69)    0.652   \-                      \-      1.526 (0.081-28.82)   0.778   \-                    \-
   Smoker                                                       6.063 (0.369-99.61)    0.207   \-                      \-      8.095 (0.934-70.13)   0.058   \-                    \-
  **p16 IHC status**                                                                                                                                                               
   Negative                                                     1                              1                               1                             1                     
   Positive                                                     0.135 (0.022-0.828)    0.030   0.192 (0.034-1.092)     0.063   0.281 (0.084-0.939)   0.039   0.281 (0.083-0.953)   0.042
  **Lymphovascular invasion**                                                                                                                                                      
   Absent                                                       1                              \-                              1                             \-                    
   Present                                                      0.486 (0.057-4.158)    0.510   \-                      \-      1.476 (0.431-5.058)   0.536   \-                    \-
  **Perineural invasion**                                                                                                                                                          
   Absent                                                       1                              \-                              1                             \-                    
   Present                                                      0.346 (0.001-101.0)    0.714   \-                      \-      0.345 (0.005-22.01)   0.616   \-                    \-
  **Pathologic T category**                                                                                                                                                        
   pT1-2                                                        1                              1                               1                             1                     
   pT3-4                                                        11.65 (2.327-58.34)    0.003   11.305 (2.173-58.803)   0.004   7.038 (2.048-24.19)   0.002   7.041 (2.023-24.51)   0.002
  **Lymph node metastasis**                                                                                                                                                        
   Absent                                                       1                              \-                              1                             \-                    
   Present                                                      1.592 (0.185-13.723)   0.657   \-                      \-      1.322 (0.285-6.132)   0.713   \-                    \-
  **TrkA expression**                                                                                                                                                              
   Low                                                          1                              \-                              1                             \-                    
   High                                                         0.021 (0.000-18.39)    0.265   \-                      \-      0.144 (0.018-1.126)   0.065   \-                    \-
  **TrkB expression**                                                                                                                                                              
   Low                                                          1                              \-                              1                             \-                    
   High                                                         0.838 (0.152-4.630)    0.839   \-                      \-      0.655 (0.173-2.478)   0.533   \-                    \-
  **PanTrk expression**                                                                                                                                                            
   Low                                                          1                              \-                              1                             \-                    
   High                                                         0.416 (0.084-2.060)    0.282   \-                      \-      0.466 (0.142-1.531)   0.208   \-                    \-

RFS, recurrence-free survival; OS, overall survival; HNSCC, head and neck squamous cell carcinoma; HR, hazard ratio; CI, confidence interval; IHC, immunohistochemistry.

Median age of 82 patients was 58.0 years.
